7.4.4.3. renal medullary carcinoma. smarcb1-deficient renal medullary carcinoma one aggressive rccs patients (~67%) present metastatic disease . even patients present seemingly localised disease may develop macro metastases shortly thereafter, often within weeks. despite treatment, median os thirteen months recent series . due infiltrative nature medullary epicentre rmc, rn favoured pn even early-stage disease. retrospective data indicate nephrectomy localised disease results superior os (16.4 vs. 7 months) compared systemic chemotherapy alone, longer survival noted patients achieved objective response first-line chemotherapy . currently established role distant metastasectomy nephrectomy presence metastases. palliative radiation therapy option may achieve regression targeted areas, prevent progression outside radiation field . renal medullary carcinoma refractory monotherapies targeted anti-angiogenic regimens including tkis mtor inhibitors . mainstay systemic treatments rmc cytotoxic combination regimens produce partial complete responses ~29% patients . prospective comparisons different chemotherapy regimens, published series used various combinations platinum agents, taxanes, gemcitabine, and/or anthracyclines . high-dose-intensity combination mvac also shown efficacy rmc although retrospective comparison show superiority mvac cisplatin, paclitaxel, gemcitabine . single-agent anti-pd-1 immune checkpoint therapy produced responses case reports, although, yet insufficient data available determine response rate approach . whenever possible, patients enrolled clinical trials novel therapeutic approaches, particularly failing first-line cytotoxic chemotherapy. 7.4.4.3.1. rare tumours knowledge systemic treatment rare tumors limited, mostly based set case reports. facts therapy renal tumours see chapter 3.5 table 3.2. metastatic collecting duct carcinoma (cdc) lowest mortality concomitant use cytoreductive nephrectomy systemic therapy . systemic therapy investigated bonsai phase ii trial. nivolumab showed cilical benefit 60 % second-line therapy cabozantinib failure . tfe3-rearranged rcc showed objective response rate 25 % ici 0 % tki prolonged os (62.4 months ici vs 10.3 tki). cabozantinib may exeption 16.6% objective response. discussed future role ici-tki combination (such nivolumab plus cabozantinib) cabozantinib plus belzutifan . tfeb-altered rcc:tfeb-rearranged rcc: general lack information regarding response moderm systemic therapy. combination ici mtor inhibitors discussed. tfeb-amplified rcc (it occurs elderly patients displays aggressive behaviour compared tfeb-rearranged rcc) treated vegfr targeting agents vegfr-tki combination . studies combine therapy tfe3- tfeb-altered rccs (because former grouping ob tumours mit family translocation rccs). one retrospective study exhibit efficacy ici ici-tki combination . study provided evidence activity cabozantinib mit trcc, durable responses observed historically vegfr-tkis icis . fumarate hydratase-deficient rcc high metastatic potential, ici monotherapies offer better disease control rate tki monotherapies. phase ii trial, orr 51 % combination erlotinib bevacizumab . trial expressed favorable response ici/tki combinational therapy comparred bevacizumab plus erlotinib . succinate dehydrogenase (sdh)-deficient rcc low risk metastasis (12 %) exception high-grade risk 70 %. due rarity disease, evidence systemic therapy . anaplastic lymphoma kinase (alk)-rearranged rcc, reports efficacy alk inhibitors, e.g. entrectinib . eloc (formerly tceb1)-mutated rcc doesnâ€™t exhibit cinically aggressive behaviour . data indicates recommendation one treatment another.